Table 2.
Hormone refractory biochemical progression-free survival according to each clinicopathological parameter
|
Univariate and multivariate analyses for hormone refractory biochemical-progression free survival rates | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Parameter |
Hormone refractory biochemical progression-fee survival rates |
Univariate analysis |
Multiivariate analyses |
||||||
| 5 years | 10 years | HR† | 95% CI†† | p | HR† | 95% CI†† | p | ||
| Age, years (median 67.0) |
<65 |
94.6 |
89.9 |
|
|
|
|
|
|
| ≥65 |
94.1 |
87.6 |
|
|
0.687 |
|
|
|
|
| PSA, mg/ml [median 15.1 (3.5−160.7)] |
<10 |
97.1 |
97.1 |
1 |
|
|
|
|
|
| 10-20< |
88.9 |
80.8 |
6.18 |
1.1, 116.8 |
0.043 |
|
|
|
|
| 20-50< |
100.0 |
100.0 |
0.0 |
0,. |
0.315 |
|
|
|
|
| ≥50 |
90.9 |
60.6 |
12.9 |
1.9, 254.0 |
0.008 |
|
|
|
|
| Clinical stage |
T1,2 |
100.0, 100.0 |
100.0, 88.9 |
1 |
|
|
1 |
|
|
| T3~4 |
90.0 |
84.8 |
7.47 |
1.4, 137.1 |
0.013* |
3.65 |
0.7, 68.6 |
0.161 |
|
| Gleason score at biopsy |
5~7 |
98.5 |
98.3 |
1 |
|
|
1 |
|
|
| ≥8 |
86.8 |
70.3 |
8.38 |
2.2, 55.0 |
0.001* |
4.73 |
1.2, 31.7 |
0.027* |
|
| Seminal vesicle invasion |
− |
98.4 |
98.4 |
1 |
|
|
1 |
|
|
| + |
88.1 |
73.1 |
7.42 |
1.9, 48.7 |
0.003* |
4.53 |
1.1, 30.1 |
0.030* |
|
| Surgical margin |
− |
100.0 |
100.0 |
|
|
|
|
|
|
| + |
93.6 |
86.7 |
|
|
0.183 |
|
|
|
|
| Microlymphatic invasion |
− |
97.2 |
95.0 |
1 |
|
|
1 |
|
|
| + |
87.9 |
74.4 |
5.33 |
1.5, 24.7 |
0.006* |
2.18 |
0.9, 12.8 |
0.140 |
|
| Microvascular invasion |
− |
96.3 |
90.5 |
|
|
|
|
|
|
| + |
92.2 |
85.6 |
|
|
0.468 |
|
|
|
|
| Perineural invasion |
− |
100.0 |
100.0 |
|
|
|
|
|
|
| + |
93.6 |
86.7 |
|
|
0.242 |
|
|
|
|
| Gleason score at prostatectomy |
5−7 |
95.7 |
89.6 |
|
|
|
|
|
|
| ≥8 | 91.4 | 71.4 | 0.114 | ||||||
†Hazard ratio by Cox proportional-hazard models
††Confidence interval